Several known breast cancer susceptibility genes with moderate-to-high risk alleles encode proteins involved in DNA damage response (DDR). As these explain less than half of the hereditary breast cancer cases, additional predisposing alleles are likely to be discovered. Many of the previous studies utilizing massive parallel sequencing have focused on the proteintruncating variants, and the role of rare missense mutations has remained poorly addressed. To identify novel susceptibility factors, we have systematically analyzed the data from our parallel sequencing of 796 DDR genes in 189 Northern Finnish hereditary breast cancer patients for rare missense variants, predicted as deleterious. Thirty-five variants were studied here for the disease association using Finnish breast cancer case (n 5 492-2,035) and control (n 5 277-1,539) cohorts. As a result, two missense variants in genes involved in DNA replication, RECQL p.I156M and POLG p.L392V, the former involving genomic and the latter mitochondrial DNA replication, showed significant association with risk of breast cancer. Rare RECQL p.I156M allele was observed in breast cancer cases only (6/1,946, 0.3%, p 5 0.043), whereas POLG p.L392V was two times more frequent in breast cancer cases (53/2,238, 2.4%) compared to controls (18/1,539, 1.2%, OR 5 2.1, 95% CI 1.2-3.5, p 5 0.010). Based on the current genetic data, both RECQL p.I156M and POLG p.L392V represent novel breast cancer predisposing alleles.
Introduction
Inherited mutations in various genomic loci are wellrecognized risk factors for breast cancer with variable levels of disease risk. 1 Most of the identified moderate-to-high risk susceptibility genes are involved in the DNA damage response (DDR), and majority of the predisposing variants in these, including the high-risk genes BRCA1 and BRCA2, and their interacting partner PALB2, are nonsense, frameshift or splice site mutations resulting in protein truncations or null alleles. [2] [3] [4] Consequently, many of the previous studies utilizing massive parallel sequencing have focused on the protein truncating variants. [5] [6] [7] However, half or more of the pathogenic mutations in the high-risk gene TP53 and in the moderate-risk genes CHEK2 and ATM are rare missense substitutions. 3, 8 For instance, in ATM the missense mutations located in the last third of the protein confer on average even higher cancer risk than truncating variants. 9 Several other genes, including PTEN, RAD51C and XRCC2, also harbor rare missense mutations associating with breast cancer susceptibility. [10] [11] [12] [13] Several explanations have been proposed for the pathogenicity of specific missense variants. Mutations that reside in the only functional domain of the protein or in highly conserved regions are likely to cause defects on protein function, whereas the presence of multiple similar domains or other repeated sequences reduce the deleterious effect of a single substitution. 3 Missense mutations producing stable protein products can also act in a dominant negative manner affecting at least some cellular functions of the protein. For example, patient-derived cells with heterozygous ATM p.V2424G mutation produced stable but defective protein, showing <10% of ATM kinase activity compared to the wild type. 14 Similarly, two variants in the BRCT domain of BRCA1, p.G1706E and p.A1708E, result in a lower level of BRCA1 recruited to DNA damage sites when compared to wild type cells or those with truncating mutations, 15 and a moderaterisk BRCA2 p.Y3035S variant causes impaired BRCA2 homology directed repair. 16 Deleterious missense mutations in other DDR genes could be expected to exist as well, and as the currently known loci account for less than half of the hereditary cases, 17 these could represent at least a part of the still unknown hereditary susceptibility to breast cancer.
We have previously performed a parallel sequencing of 796 DDR genes in Finnish breast cancer patients with an indication of hereditary disease susceptibility, and studied the disease association of the protein truncating variants. This led to the identification of three recurrent breast cancerassociating rare alleles, MCPH1 p.R304Vfs*3, TEX15 p.L2418Ffs*6 and FANCD2 c.2715 1 1 G > A. 7 Rare mutations in RECQL have also recently been associated with breast cancer susceptibility, [20] [21] [22] [23] [24] [25] for which our results now provide further evidence. POLG encodes the catalytic subunit of DNA polymerase g responsible for the replication of mitochondrial DNA (mtDNA), 26 and our study proposes a novel link between POLG missense variants and inherited breast cancer predisposition.
Materials and Methods

Detection and bioinformatics analyses of the missense variants
The initial discovery of the missense variants was performed by targeted next-generation sequencing (NGS) of 796 DDR genes in 189 Northern Finnish breast cancer patients with indication of hereditary disease susceptibility (referred hereafter as NGS hereditary BC cohort), as previously described. 18 Annotation of the variants was performed with Annovar, 27 where the effect of the identified missense substitutions on the protein function was evaluated based on SIFT, 28 Poly- 
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58 years) and 501 were diagnosed at the Kuopio University Hospital as part of the Kuopio Breast Cancer project (KBCP) during the years 1990-1995 32 (mean age at diagnosis 58 years). Clinical parameters for the unselected breast cancer cases were obtained from the pathology reports and included TNM (tumor, nodes, metastasis) classification, hormonal receptor status, tumor grade, tumor histology, Ki67 status and age at diagnosis. 32 Briefly, estrogen receptor (ER) and progesterone receptor (PR) positive staining was defined as nuclear immunostaining of the tumor cells as 1-10% for weak, 10-50% for moderate, or >50% for strong and no staining for the negative receptor status. HER2 expression was studied by immunohistochemistry (positivity defined as weak, moderate or strong levels of staining and negativity completely negative staining) and chromogenic in situ hybridization (CISH). Cut-off values used for Ki67 were negative (0), weak (1), moderate (2) and strong (3). Control subjects were cancer-free Northern Finnish Red cross blood donors, total n 5 1,139, females n 5 697 (mean age 39 years), males n 5 442 (mean age 43 years) and cancer-free females matched for age and long-term area-of-residence for the cases in KBCP project (n 5 456). 32 Northern Finnish BRCA1/2 mutation negative familial (n 5 143) and young (n 5 60) breast cancer cases, forming a single hereditary cohort, n 5 203 (including 132 BRCA1/2 mutation negative cases from the NGS hereditary BC cohort), was used for evaluation of the frequencies of POLG p.L392V and RECQL p.I156M variants. The familial cases (n 5 143) included (1) 81 patients from families with three or more breast and/or ovarian cancers in first-or second-degree relatives, (2) 24 patients with two cases of breast, or breast and ovarian cancer in first-or second-degree relatives, of which at least one had early disease onset (<35 years), bilateral breast cancer, or multiple primary tumors including breast or ovarian cancer in the same individual and (3) 38 patients with two cases of breast cancer in first-or second-degree relatives. The young breast cancer cases (n 5 60) were diagnosed with breast cancer at or below the age of 40 (median 38, range 25-40 years) and were unselected for a family history of cancer. These cases were combined with the familial cohort to form a single hereditary cohort (n 5 203), based on the assumption that when a woman below the age of 40 years develops breast cancer, a hereditary predisposition may be suspected regardless of the family history. 33 Our study included informed consent from all the participating individuals, and it was approved by the Ethical Board of the Northern Ostrobothnia Health Care District, the Ethical committee of the University of Eastern Finland and Kuopio University Hospital and the Ministry of Social Affairs and Health in Finland.
Variant detection
All samples were genomic DNA extracted from peripheral blood. Variant screenings were performed using High Resolution Melt (HRM) analysis (CFX96, Bio-Rad, Hercules, CA) with Type-It HRM reagents (Qiagen, Hilden, Germany), and MassARRAYV R and iPLEXV R Gold (Sequenom, Inc., San Diego, CA). Verification of detected variants was done with Sanger sequencing (ABI3130xl, Applied Biosystems, Foster City, CA).
Loss of heterozygosity (LOH) analysis of POLG p.L392V carrier tumors
Tumor DNA from POLG p.L392V carriers was extracted from 11 formalin-fixed, paraffin-embedded (FFPE) tumors using both phenol-chloroform-isoamyl alcohol extraction and GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany) as parallel methods. LOH was analyzed by sequencing of a 136-bp amplicon flanking the p.L392V site. The allelic ratios between tumor and the corresponding normal DNA sample were assessed by comparing the peak height values from the sequence chromatograms (ab1 Peak Reporter, Applied Biosystems, Foster City, CA). The allelic imbalance (AI) values were calculated for each sample pair, and the ones with AI >1.67 or <0.60 were considered as having LOH. 34 Statistical analyses v 2 test or Fisher's exact test was used to compare the carrier frequencies between cases and controls, and also for the comparison of the clinical parameters between the POLG p.L392V carrier and non-carrier patients. The 10-year breast cancer specific survival (BCSS) between the POLG p.L392V carriers (n 5 48) and non-carriers (n 5 899) from the unselected breast cancer cohort was compared using univariate Kaplan-Meier analysis and Cox regression. Survival time was calculated as the time from the date of diagnosis to the last follow-up or death. All statistical analyses were performed with IBM SPSS Statistics 22.0 for Windows (SPSS, Inc., Chicago, IL). All p-values were two-sided and values <0.05 were considered statistically significant.
Results
Case-control analysis for the identification of breast cancer associated alleles
The validation and filtering steps presented in Supporting Information Figure S1 were performed to select the potential breast cancer associating missense variants for the case-control association analyses. Briefly, filtering was based on the following: (1) exclusion of variants predicted as benign or as polymorphism by any of the three used software, (2) exclusion of variants with minor allele frequency (MAF) over 1% in dbSNP or among the Finns in the ExAC database, (3) inclusion of recurrent variants (observed at least twice) in any of the studied genes among the 189 breast cancer patients and inclusion of singletons in the previously identified breast cancer susceptibility genes and (4) exclusion of variants with known ClinVar status or those already extensively studied previously. In total, 35 variants met the criteria and were studied in unselected breast cancer cases and healthy controls. Majority of these turned out to be very rare or had similar frequencies in analyzed breast cancer cases and controls (Supporting Information Table S1 ), curiously also including BRCA2 missense change, p.S3291C, at the evolutionarily conserved phosphorylation site in the C-terminus of the protein. 35, 36 Of the analyzed variants, NUFIP1 p.W14S was detected in controls only, whereas AXIN2 p.T308M was absent from the unselected cases and controls. Two patients in the NGS hereditary cohort carried this AXIN2 variant and both were diagnosed below the age of 50 (47 and 49 years, respectively). The AXIN2 p.T308M carriers had family history of many different cancer types (gastric and uterine cancer, in addition to several breast cancer cases), but unfortunately the family member DNA samples were not available for testing the mutation segregation, thus leaving its impact on cancer predisposition unknown. Two potential cancer predisposing variants were studied in more detail: POLG p.L392V, which was significantly enriched in the breast cancer cases, and RECQL p.I156M. Although RECQL p.I156M showed only a borderline association with breast cancer, it occurred in recently established breast cancer susceptibility gene, 23 and was recurrent in the breast cancer cases but absent from healthy controls.
RECQL variant p.I156M is observed only in cases and shows association with breast cancer
The frequency of the p.I156M variant (c.T468G) in RECQL was evaluated in total of 1,946 breast cancer cases (1,744 cases unselected for a family history of cancer or age at disease onset, and 202 BRCA1/2 mutation negative hereditary cases) and in 1,408 healthy controls (Table 1 ). Although remaining rare, the highest prevalence for the RECQL p.I156M was observed among BRCA1/2 mutation negative hereditary cases (2/202, 1.0%, p 5 0.016), whereas no carriers were observed in controls. Four carriers were identified in the unselected cohort 4/1,744 (0.2%, p 5 0.133), this variant thus showing statistically significant association with risk of breast cancer (all BC cohort 6/1,946, p 5 0.043, Table 1 ). The mean age at disease onset for all p.I156M carriers was 60 years (range 52-72 years), which did not differ from the mean in the unselected cohort (58 years, range 28-93 years). Data from pathology reports were available for five carriers (Supporting Information Table S2 ), the tumors being all of ductal origin. Curiously, only one of the tumors was triple-negative (ER-/PR-/HER2-), a subtype that has previously been associated with defects in other DDR genes. 37 In the hereditary cohort, one carrier had family history of breast cancer (family 2), whereas the other had also one case of ovarian cancer (family 1) (Fig. 1) , which has also been reported in previously identified RECQL families. 23, 25 In family 1, altogether three breast cancer cases were confirmed as carriers, two of them having a bilateral disease. In family 2, the only additional breast cancer case (age at diagnosis 69 years) that was available for testing turned out to be a non-carrier. Family history was available also for three out of four carriers from the unselected cohort. Two of them had positive family history for ovarian cancer (families 3 and 4), and two for pancreatic cancer (families 3 and 5, altogether three cases) (Fig. 1) . The likely deleterious effect of the RECQL p.I156M alteration is further supported by its localization to functionally important ATPase domain and evolutional conservation at this locus in various species (Fig. 2a) .
POLG variant p.L392V is twice more frequent in the breast cancer cases POLG missense variant p.L392V (c.C1174G) was relatively frequent in the analyzed cohorts and showed significant twofold enrichment in the breast cancer cases (53/2,238, 2.4%) when compared to controls (18/1,539, 1.2%) (OR 5 2.1, 95% CI 5 1.2-3.5, p 5 0.010) ( Table 1 ). The carrier frequencies were similar both in the unselected breast cancer cohort (2.4%) and in the BRCA1/2-mutation negative hereditary cohort (2.5%). POLG encodes the catalytic subunit of DNA polymerase g responsible for the replication of mitochondrial DNA, 26 and the substituted amino acid L392 locates to functionally important exonuclease domain of the protein.
Sequence alignments revealed evolutionary conservation among several species at this particular site (Fig. 2b) , 
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suggesting functional importance. As mitochondrial changes are expected to take place particularly during the tumor development and progression, association with tumor characteristics and survival were studied. No statistically significant differences were detected either in BCSS (Supporting Information Fig. S2 ) or tumor characteristics (Supporting Information Table S3 ) between POLG p.L392V carriers and non-carriers, although patients with available information of Ki67 status showed higher cell proliferation state among the carriers with borderline significance (OR 5 3.76, 95% CI 5 0.99-14.34, p 5 0.06). This indicates that predisposition is not restricted to any subtype. There was no difference in the disease onset between the carriers (mean 5 57 years) and non-carriers (mean 5 58 years), and there was no strong evidence for LOH (wild type allele was lost only in one out of eleven studied FFPE archived tumors, data not shown). Absence of LOH is typical for moderate breast cancer risk alleles. 38 Unfortunately, due to the poor quality of mtDNA in the FFPE samples, the effect of POLG p.L392V on mtDNA depletion in the carrier tumors could not be studied.
Discussion
The extensive case-control association analysis performed here for the rare, presumably deleterious missense variants in genes encoding important players in the DDR pathway identified two potentially breast cancer predisposing alleles, RECQL p.I156M and POLG p.L392V. RECQL is a DNA helicase required for the maintenance of genomic stability, whereas POLG encodes the catalytic subunit of DNA polymerase g, which is the only human DNA replicase known to function in the mitochondria. 19, 26 Based on its frequency in the analyzed cohorts, we propose RECQL p.I156M to be a rare breast cancer associating variant in the Finnish population. Three out of the six currently identified families had also positive history for ovarian cancer, indicating that this could be a part of the cancer spectrum associated with RECQL mutations, which is in line with the data from RECQL positive families identified in previous studies. 23, 25 As a member of RecQ helicases, which unwind double-stranded DNA during DNA replication, recombination and repair, RECQL can be considered as an important guardian of the genome. 19, 39 Indeed, RECQLdeficient cells show increased load of DNA damage together with spontaneous sister chromatid exchanges, 40, 41 and several of the breast cancer associated truncating and missense mutations have been reported to completely abolish the helicase activity in vitro. 25 The currently identified p.I156M variant locates to the helicase ATP-binding domain, where also two of the previously reported helicase disrupting missense variants, p.A195S and p.R215Q, reside. Altogether, current results add further evidence to the role of rare RECQL variants in inherited breast cancer predisposition, although the exact disease penetrance of these might range from moderate-to-high. [23] [24] [25] 42 The other currently observed breast cancer associating variant, POLG p.L392V, was relatively common in the analyzed cohorts and showed twofold enrichment in the breast cancer cases, indicating a moderate effect on disease predisposition. POLG p.L392V affects an evolutionarily highly conserved residue in the exonuclease domain of the protein that is responsible for the proofreading activity during mtDNA replication. 43 Accurate replication of mtDNA is highly important for the cells, since several mitochondrial genes encode proteins crucial for the cellular energy production through oxidative phosphorylation (OXPHOS). Mutations in POLG result in mtDNA depletion and increased mtDNA mutation rate, 26 which can lead to severe, mostly recessively inherited mitochondrial diseases. These POLG-related disorders include Alpers-Huttenlocher syndrome, ataxia-neuropathy disorders and progressive external ophthalmoplegia with overlapping signs and symptoms affecting muscle-, nerveand brain-related functions. 44, 45 Even though POLG p.L392V
is currently classified as a variant with uncertain significance for these conditions, 46 in yeast models it has been shown to have an effect on POLG function, manifested by decreased mtDNA content after treatment with nucleoside reverse transcriptase inhibitor. 47 Whereas mitochondrial diseases affect particularly tissues whose cells do not divide constantly, defects in OXPHOS and control of oxidative stress due to mtDNA mutations and depletion have also been reported in cancer of various organs, including breast cancer. 48 Decreased OXPHOS has even been proposed as one of the emerging hallmarks of cancer through its connection to an increased cellular glycolytic energy production. 49 POLG variants have also been reported to play a direct role in cancer development, as another substitution at the exonuclease domain, p.T251I, has been shown to increase tumorigenicity in breast cancer cells. 21 Another study has linked POLG promoter region SNP (rs2856268), leading to higher levels of POLG mRNA expression, to protective effect for breast cancer when homozygous (OR 5 0.81).
20
In conclusion, our study revealed that many rare missense variants in DDR genes with predicted deleterious effect on the protein have similar frequencies in breast cancer cases and healthy population. Thus, these are unlikely high-risk susceptibility factors for breast cancer, although some lowpenetrance or modifier effects cannot be excluded. Based on the current genetic data, two germline variants, p.I156M in RECQL and p.L392V in POLG, are novel breast cancer predisposing alleles. Of these, POLG p.L392V has a moderate effect on breast cancer risk, whereas for RECQL p.I156M the effect could potentially be higher. Although rare and showing enrichment in the Finnish population, according to ExAC database 50 both alleles exist also outside of Finland but with lower frequency. Thus, these and possibly also other rare variants predicted as deleterious in POLG and RECQL genes warrant further studies in other populations. Addition of POLG p.L392V and RECQL p.I156M to the growing list of predisposition alleles identified in DDR genes with various functions underscores that diverse mechanisms are likely to be relevant to breast cancer pathogenesis.
